Effect of disease-modifying treatment on coronavirus disease 2019 vaccination in patients with multiple sclerosis

被引：0
|
作者：
D'haeseleer, M. [1 ]
Van Remoortel, A. [1 ]
D'hooghe, M. [1 ]
Della Faille, L. [1 ]
Nagels, G. [2 ,3 ]
Van Schependom, J. [4 ]
机构：
[1] Natl Multiple Sclerose Centrum NMSC, Melsbroek, Belgium
[2] Vrije Univ Brussel VUB, Ctr Neurosci C4N, NEUR, Brussels, Belgium
[3] Vrije Univ Brussel VUB, AIMS, Brussels, Belgium
[4] Vrije Univ Brussel VUB, Dept Elect & Informat ETRO, Brussels, Belgium
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-172
引用
收藏
页码：429 / 430
页数：2
相关论文
共 50 条
  • [21] Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
    Spessotto, Caroline Vieira
    Cavalli, Hanaie
    Biondo Eboni, Audred Cristina
    Machado, Rafael Berlezi
    Mousquer, Analara Munardi
    Palazzo, Lara Both
    Finkelsztejn, Alessandro
    Magno Goncalves, Marcus Vinicius
    Sato, Henry Koiti
    Siquineli, Fable
    Fragoso, Yara Dadalti
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2016, 74 (08) : 617 - 620
  • [22] Corticosteroids and disease-modifying antirheumatic drugs for coronavirus disease 2019 in patients with rheumatoid arthritis
    Chen, Yu-Han
    Lee, Yuan-Ti
    Ma, Kevin Sheng-Kai
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (07) : 1391 - 1392
  • [23] Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review
    Jamali, Elham
    Shapoori, Shima
    Farrokhi, Majid Reza
    Vakili, Sina
    Rostamzadeh, Davoud
    Iravanpour, Farideh
    Oliaee, Razieh Tavakoli
    Jafarinia, Morteza
    VIRAL IMMUNOLOGY, 2023, 36 (06) : 368 - 377
  • [24] Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Vartanian, TK
    Zamvil, SS
    Fox, E
    Sorensen, PS
    NEUROLOGY, 2004, 63 (11) : S42 - S49
  • [25] Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
    Soroush Moradi
    Maryam Masoumi
    Somayeh Mohammadi
    Jamshid Vafaeimanesh
    Mohaddeseh Mohseni
    Hossein Mahdavi
    Armin Aryannejad
    Internal and Emergency Medicine, 2021, 16 : 919 - 923
  • [26] Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
    Moradi, Soroush
    Masoumi, Maryam
    Mohammadi, Somayeh
    Vafaeimanesh, Jamshid
    Mohseni, Mohaddeseh
    Mahdavi, Hossein
    Aryannejad, Armin
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (04) : 919 - 923
  • [27] Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
    Morillo Verdugo, Ramon
    Ramirez Herraiz, Esther
    Fernandez-Del Olmo, Raquel
    Roig Bonet, Montserrat
    Valdivia Garcia, Maria
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 261 - 272
  • [28] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Grebenciucova, Elena
    Pruitt, Amy
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (11)
  • [29] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [30] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
12345